Ming Yeh Lee, Victor Ritter, Blake Shaw, Johannes O Ferstad, Ramesh Johari, David Scheinker, Franziska Bishop, Manisha Desai, David M Maahs, Priya Prahalad
{"title":"Addressing Disparities Using Continuous Glucose Monitors and Remote Patient Monitoring for Youth With Type 1 Diabetes.","authors":"Ming Yeh Lee, Victor Ritter, Blake Shaw, Johannes O Ferstad, Ramesh Johari, David Scheinker, Franziska Bishop, Manisha Desai, David M Maahs, Priya Prahalad","doi":"10.1177/19322968241305612","DOIUrl":"https://doi.org/10.1177/19322968241305612","url":null,"abstract":"<p><strong>Background: </strong>Youth with type 1 diabetes (T1D) and public insurance have lower diabetes technology use. This pilot study assessed the feasibility of a program to support continuous glucose monitor (CGM) use with remote patient monitoring (RPM) to improve glycemia for youth with established T1D and public insurance.</p><p><strong>Methods: </strong>From August 2020 to June 2023, we provided CGM with RPM support via patient portal messaging for youth with established T1D on public insurance with challenges obtaining consistent CGM supplies. We prospectively collected hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>), standard CGM metrics, and diabetes technology use over 12 months.</p><p><strong>Results: </strong>The cohort included 91 youths with median age at enrollment 14.7 years, duration of diabetes 4.4 years, 33% non-English speakers, and 44% Hispanic. Continuous glucose monitor data were consistently available (≥70%) in 23% of the participants. For the 64% of participants with paired HbA<sub>1c</sub> values at enrollment and study end, the median HbA<sub>1c</sub> decreased from 9.8% to 9.0% (<i>P</i> < .001). Insulin pump users increased from 31 to 48 and automated insulin delivery users increased from 11 to 38.</p><p><strong>Conclusions: </strong>We established a program to support CGM use in youth with T1D and barriers to consistent CGM supplies, offering lessons for other clinics to address disparities with team-based, algorithm-enabled, remote T1D care. This real-world pilot and feasibility study noted challenges with low levels of protocol adherence and obtaining complete data in this cohort. Future iterations of the program should explore RPM communication methods that better align with this population's preferences to increase participant engagement.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241305612"},"PeriodicalIF":4.1,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robert M Havey, Avinash G Patwardhan, Rodney M Stuck, Stephanie A Keen, Muturi G Muriuki
{"title":"Adherence Monitor for Measurement of Removable Cast Walker Wear-Time: Multiple Sensors and Predictive Analytics Improve Accuracy.","authors":"Robert M Havey, Avinash G Patwardhan, Rodney M Stuck, Stephanie A Keen, Muturi G Muriuki","doi":"10.1177/19322968241304751","DOIUrl":"https://doi.org/10.1177/19322968241304751","url":null,"abstract":"<p><strong>Background: </strong>Treatment of diabetes and its complications is a primary health care expense. Up to 25% of people with diabetes will develop diabetic foot ulcers (DFUs). Removable cast walker (RCW) boots commonly prescribed for DFU treatment, promote healing, and provide offloading and wound protection. Patient RCW removal for hygiene and wound care can lead to decreased adherence and treatment effectiveness. This study evaluated a new system for wear-time adherence measurement using multiple sensor types.</p><p><strong>Methods: </strong>An electronic wear-time monitor was developed, which included internal and external temperature sensors, an accelerometer, and capacitive proximity foot and ankle sensors. Time-stamped and date-stamped data were saved once per minute for up to 22 days. Ten healthy volunteer subjects were recruited to wear an RCW for two weeks while keeping a diary of don/doff times. Sensor data were then compared with volunteers' wear diaries using confusion matrix predictive analytics.</p><p><strong>Results: </strong>Algorithms were developed for data processing. Correlation coefficients between algorithms and diaries were calculated for individual and multiple sensor combinations. Differential temperature and accelerometer algorithms were significantly better at predicting subject wear-time than individual temperature sensor algorithms (<i>P</i> = .009, <i>P</i> = .001, respectively). Foot proximity had significantly better correlation with subject diaries than temperature (<i>P</i> = .024), and acceleration algorithms (<i>P</i> = .005). Multi-sensor analysis showed high correlation (.96) with wear-time from subject diaries.</p><p><strong>Conclusions: </strong>Removable cast walker wear-time can be accurately determined using an electronic data recorder and multiple sensors. Wear-time measurement accuracy can be improved using algorithms that operate on data from multiple sensors that use a variety of sensor technologies.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241304751"},"PeriodicalIF":4.1,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Behavioral Intervention Functions in Type 2 Diabetes Apps: Literature Review.","authors":"Elia Gabarron, Pietro Randine, Eirik Årsand","doi":"10.1177/19322968241305646","DOIUrl":"https://doi.org/10.1177/19322968241305646","url":null,"abstract":"<p><strong>Background: </strong>As type 2 diabetes (T2D) is expected to increase, self-management becomes more crucial. Mobile apps are increasingly supporting self-management with tasks like blood glucose monitoring and medication management. Understanding the behavioral intervention functions used by diabetes apps today, is essential for improving future apps and systems for diabetes management.</p><p><strong>Objective: </strong>To analyze the behavioral intervention functions used in apps for managing T2D that integrate the three main elements: medication management, nutrition tracking, and blood glucose management.</p><p><strong>Methods: </strong>We conducted a literature review on T2D diabetes apps using SCOPUS, PubMed, and PsycINFO. After screening and removing duplicates, we analyzed app details and behavioral intervention functions based on the Behavior Change Wheel (BCW) framework.</p><p><strong>Results: </strong>We reviewed 644 scientific publications describing diabetes apps in clinical studies, narrowing it down to 20 studies, including 16 unique apps, after screening and exclusions. These studies were published between 2016 and 2024. Among the identified apps, automatic processing of medication data was reported in one study, while blood glucose data were automatically processed in 13 studies. Nutrition data processing varied. Most apps used <i>Enablement</i> and <i>Persuasion</i> as behavioral intervention functions, with <i>Education</i> and <i>Training</i> reported less frequently. <i>Environmental Restructuring, Incentivization, Coercion, Restriction</i>, and <i>Modeling</i> were not reported as being used in any studies.</p><p><strong>Conclusions: </strong>This review shows that while <i>Enablement</i> and <i>Persuasion</i> are common, other behavioral intervention functions seem to be underused or underreported. Future research could explore the potential of integrating additional behavioral intervention functions to enhance diabetes app efficacy and users' self-management.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241305646"},"PeriodicalIF":4.1,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Effective Use by Primary Care Clinicians of a Comprehensive Computerized Insulin Dose Adjustment Algorithm.","authors":"Mayer B Davidson","doi":"10.1177/19322968241306127","DOIUrl":"https://doi.org/10.1177/19322968241306127","url":null,"abstract":"<p><p>Primary care clinicians (PCCs) manage 90% of patients with diabetes, 30% of whom require insulin with a substantial number poorly controlled because of the challenges that PCCs face (time constraints and lack of experience). The author has developed Federal Drug Administration cleared and Conformite Europeenne mark registered comprehensive computerized insulin dose adjustment algorithms (CIDAAs) to enable PCCs to significantly lower HbA1c levels in insulin-requiring patients. Reports sent to PCCs contain scatter plots of glucose readings, their organization into pre- and postprandial and before bedtime values, their analyses, and recommendations for insulin dose adjustments (if indicated) that the PCC can accept or modify. The glucose readings are provided to the CIDAAs for analysis at either in-person visits or remotely. The new doses accepted by PCCs serve as the basis for the subsequent report. Published studies evaluating this comprehensive CIDAA involved 104 poorly controlled patients taking insulin for greater than or equal to six months who were independently managed by PCCs. Over four to six months, initial HbA1c levels of 9.7% fell by 1.7%. Combining these results with 138 other better controlled patients in real-world situations, initial measured and estimated HbA1c levels of 8.3% fell by 0.7% in 6.4 months enabling PCCs to significantly improve glycemic control. Other advantages of PCCs utilizing these comprehensive CIDAAs are saving time for PCCs so that they can address non-diabetes issues and/or see other patients and ongoing PCC education in adjusting insulin doses by matching glucose patterns and dose-change recommendations with subsequent glycemic responses.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241306127"},"PeriodicalIF":4.1,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sebastian F Petry, Marie Bienhaus, Friedrich W Petry, Johannes K Petry, Lutz Heinemann, Stefan Gäth
{"title":"Quantification of Different Types of Waste and Batteries Associated With the Widespread Usage of Continuous Glucose Monitoring Systems.","authors":"Sebastian F Petry, Marie Bienhaus, Friedrich W Petry, Johannes K Petry, Lutz Heinemann, Stefan Gäth","doi":"10.1177/19322968241305161","DOIUrl":"https://doi.org/10.1177/19322968241305161","url":null,"abstract":"<p><strong>Background: </strong>People with diabetes benefit from continuous glucose monitoring (CGM) systems. A downside of these valuable aids for diabetes management is the generation of a tremendous amount of waste. This study aimed to quantify this CGM-related waste.</p><p><strong>Method: </strong>Twenty-four used CGM sensors from two different manufacturers (8× FreeStyle Libre 2, 11× FreeStyle Libre 3, and 5× Dexcom G7) were dismantled manually and separated in case, circuit board, and battery. Each component as well as included packaging, applicator, and leaflet were weighed separately.</p><p><strong>Results: </strong>Packaging, applicators, and leaflets accounted for most of the waste (FL2: 93.4 g; FL3: 58 g; G7: 108.1 g). The plastic case contributed mainly to the total sensor weight (FL2: 1.9 g/63% of 3.3 g; FL3: 0.5 g/49% of 1.1 g; G7: 1.9 g/59% of 3.2 g), whereas the weight of the electronic circuit board and battery varied (FL2: 0.8 g/25%, 0.4 g/12%; FL3: 0.2 g/17%, 0.4 g/34%; G7: 0.7 g/22%, 0.6 g/19%). Extrapolating these data based on annual worldwide usage of around 230 million glucose sensors, approximately 20,000 tons of packaging, applicators, and leaflets and 580 tons of glucose sensors are disposed of, including about 340 tons of casings, 130 tons of circuit boards, and 110 tons of batteries.</p><p><strong>Conclusions: </strong>Our data highlight the potential for optimized resource utilization by reduction of packaging, sensor size, longer application periods, implementation of multiuse applicators, and the need for recycling options.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241305161"},"PeriodicalIF":4.1,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alessandra T Ayers, Cindy N Ho, Emma Friedman, Juan Espinoza, Shahid N Shah, David C Klonoff
{"title":"How the Diabetes Research Hub Will Modernize and Enhances Diabetes Data Utilization.","authors":"Alessandra T Ayers, Cindy N Ho, Emma Friedman, Juan Espinoza, Shahid N Shah, David C Klonoff","doi":"10.1177/19322968241306129","DOIUrl":"https://doi.org/10.1177/19322968241306129","url":null,"abstract":"<p><p>The Diabetes Research Hub (DRH) is a centralized data management system and repository that will revolutionize how diabetes data are gathered, stored, analyzed, and utilized for research. By harnessing advanced analytics for large datasets, the DRH will support a nuanced understanding of physiological patterns and treatment effectiveness, ultimately advancing diabetes management and patient outcomes. This is an opportune time for researchers who are collecting continuous glucose data and related physiological data sources, to leverage the capabilities of the DRH to enhance the value of their data.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241306129"},"PeriodicalIF":4.1,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.","authors":"Sujatha Seetharaman, Eda Cengiz","doi":"10.1177/19322968241305641","DOIUrl":"https://doi.org/10.1177/19322968241305641","url":null,"abstract":"<p><strong>Background: </strong>Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, leading to lifelong insulin dependence. Despite advancements in insulin therapies and glucose monitoring, maintaining optimal blood glucose control remains challenging with common issues like weight gain and glucose variability. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), approved for type 2 diabetes and obesity, are being explored off-label for T1D.</p><p><strong>Case report: </strong>This case series investigates the effectiveness of GLP-1 RAs, mainly semaglutide and tirzepatide, as an adjunct therapy to insulin in adolescents and young adults (AYA) with T1D, in a single center, providing real-world insights and highlighting practical issues.</p><p><strong>Discussion: </strong>Most patients had obesity, consistent with typical indication for use in AYA. Common gastrointestinal side effects improved with dose titration, but careful monitoring is needed for persistent symptoms. One patient developed an eating disorder, underscoring the need for vigilance. Insurance and medication shortage issues impacted treatment continuity, highlighting the need for better support. Glycemic parameters improved in most patients, with weight reduction in several patients with obesity, and no reported diabetic ketoacidosis.</p><p><strong>Conclusions: </strong>GLP-1 RAs can be a beneficial adjunct therapy in T1D, improving glycemic control, reducing insulin needs, and supporting weight management, while potentially preventing long-term cardiovascular and renal complications.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241305641"},"PeriodicalIF":4.1,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Continuous Glucose Monitoring in Comorbid Dementia and Diabetes: The Evidence So Far.","authors":"Busra Donat Ergin, Kieran Gadsby-Davis, Katharina Mattishent, Ketan Dhatariya, Nikki Garner, Michael Hornberger","doi":"10.1177/19322968241301058","DOIUrl":"https://doi.org/10.1177/19322968241301058","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) and dementia are two of the leading chronic diseases in aging and are known to influence each other's disease progression. There is well-established evidence that T2DM increases the risk for cognitive decline and dementia. At the same time, people with cognitive changes or dementia can find it difficult to manage their diabetes, resulting in hyper- or hypoglycemic events which can exacerbate the dementia disease progression further. Monitoring of glucose variability is, therefore, of critical importance during aging and when people with T2DM develop dementia. The advent of continuous glucose monitoring (CGM) has allowed the monitoring of glucose variability in T2DM more closely. The CGM seems to be highly feasible and acceptable to use in older people with T2DM and has been shown to significantly reduce their hypoglycemic events, often resulting in falls. Less is known as to whether CGM can have a similar beneficial effect on people with T2DM who have cognitive impairment or dementia in community or hospital settings.</p><p><strong>Aims: </strong>The current perspective will explore how CGM has made an impact on T2DM management in older people and those with comorbid cognitive impairment or dementia. We will further explore opportunities and challenges of using CGM in comorbid T2DM and dementia in community and hospital settings.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241301058"},"PeriodicalIF":4.1,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Heat-Stable Insulins: Any Progress?","authors":"Lutz Heinemann","doi":"10.1177/19322968241305383","DOIUrl":"10.1177/19322968241305383","url":null,"abstract":"<p><p>Millions of people with diabetes have no or only limited access to electricity that limits their ability to store insulin according to the recommendations of the insulin manufacturer in general. At the same time, environmental temperatures are increasing in many countries which have a negative impact on the glucose-lowering effect of insulin not stored adequately. Therefore, the availability of heat-stable insulin formulations that do not require constant cooling would be of help for many patients; however, despite this clinical need, apparently not many are in clinical development. This commentary discusses the different aspects and approaches that are of relevance in this context.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241305383"},"PeriodicalIF":4.1,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fiorella Sotomayor, Reynier Hernandez, Chikara Gothong, Monica Y Choe, Garrett I Ash, William Scott, Lillian Pinault, Fernando Gomez-Peralta, Marc R Blackman, Lakshmi G Singh, John D Sorkin, Elias K Spanakis
{"title":"Utilizing a Novel Telemedicine Clinic for Managing Patients With Type 2 Diabetes: A Six-Month Randomized Control Trial Pilot Study.","authors":"Fiorella Sotomayor, Reynier Hernandez, Chikara Gothong, Monica Y Choe, Garrett I Ash, William Scott, Lillian Pinault, Fernando Gomez-Peralta, Marc R Blackman, Lakshmi G Singh, John D Sorkin, Elias K Spanakis","doi":"10.1177/19322968241305627","DOIUrl":"10.1177/19322968241305627","url":null,"abstract":"","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241305627"},"PeriodicalIF":4.1,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}